{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:03:09Z","timestamp":1777518189492,"version":"3.51.4"},"reference-count":252,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01588"],"award-info":[{"award-number":["PI19\/01588"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gilead Sciences (Spain)","award":["CLD19\/00121"],"award-info":[{"award-number":["CLD19\/00121"]}]},{"DOI":"10.13039\/501100005676","name":"Fundaci\u00f3n Josep Carreras Contra la Leucemia","doi-asserted-by":"publisher","award":["."],"award-info":[{"award-number":["."]}],"id":[{"id":"10.13039\/501100005676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"Fundaci\u00f3n Bancaria Caixa d\u2019Estalvis i Pensions de Barcelona","doi-asserted-by":"publisher","award":["."],"award-info":[{"award-number":["."]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The incidence of lymphomas is increased in people living with HIV (PLWH). Aggressive B-cell non-Hodgkin lymphomas (NHLs) are the most common and are considered an AIDS-defining cancer (ADC). Although Hodgkin lymphoma (HL) is not considered an ADC, its incidence is also increased in PLWH. Among all HIV-related lymphomas (HRL), the prevalence of Epstein\u2013Barr virus (EBV) is high. It has been shown that EBV is involved in different lymphomagenic mechanisms mediated by some of its proteins, contributing to the development of different lymphoma subtypes. Additionally, cooperation between both HIV and EBV can lead to the proliferation of aberrant B-cells, thereby being an additional lymphomagenic mechanism in EBV-associated HRL. Despite the close relationship between EBV and HRL, the impact of EBV on clinical aspects has not been extensively studied. These lymphomas are treated with the same therapeutic regimens as the general population in combination with cART. Nevertheless, new therapeutic strategies targeting EBV are promising for these lymphomas. In this article, the different types of HRL are extensively reviewed, focusing on the influence of EBV on the epidemiology, pathogenesis, clinical presentation, and pathological characteristics of each lymphoma subtype. Moreover, novel therapies targeting EBV and future strategies to treat HRL harboring EBV are discussed.<\/jats:p>","DOI":"10.3390\/cancers13215534","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T09:11:32Z","timestamp":1636017092000},"page":"5534","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Clinical and Therapeutic Implications of Epstein\u2013Barr Virus in HIV-Related Lymphomas"],"prefix":"10.3390","volume":"13","author":[{"given":"Miriam","family":"Verdu-Bou","sequence":"first","affiliation":[{"name":"Lymphoid Neoplasms Group, Josep Carreras Leukaemia Research Institute, Can Ruti Campus, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Tapia","sequence":"additional","affiliation":[{"name":"Department of Pathology, Germans Trias i Pujol Hospital, Universitat Aut\u00f2noma de Barcelona, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agueda","family":"Hernandez-Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Germans Trias i Pujol Hospital, Universitat Aut\u00f2noma de Barcelona, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-6013","authenticated-orcid":false,"given":"Jose-Tomas","family":"Navarro","sequence":"additional","affiliation":[{"name":"Lymphoid Neoplasms Group, Josep Carreras Leukaemia Research Institute, Can Ruti Campus, 08916 Badalona, Spain"},{"name":"Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia-Germans Trias i Pujol Hospital, 08916 Badalona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1093\/cid\/ciaa1016","article-title":"Deaths Attributable to Cancer in the US Human Immunodeficiency Virus Population during 2001\u20132015","volume":"72","author":"Horner","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1055-9965.EPI-20-1045","article-title":"Spectrum and Incidence Trends of AIDS- and Non\u2013AIDS-Defining Cancers between 2010 and 2015 in the French Dat\u2019AIDS Cohort","volume":"30","author":"Lions","year":"2021","journal-title":"Cancer Epidemiol. Prev. Biomark."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Meyers, C. (2019). AIDS-Associated Malignancies. HIV\/AIDS-Associated Viral Oncogenesis, Springer International Publishing. Cancer Treatment and Research.","DOI":"10.1007\/978-3-030-03502-0"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","article-title":"Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study","volume":"43","author":"Palella","year":"2006","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/canjclin.55.4.229","article-title":"Recent Advances in Acquired Immunodeficiency Syndrome (AIDS)-Related Lymphoma","volume":"55","author":"Lim","year":"2005","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/CCO.0b013e3283560697","article-title":"Impact of Highly Effective Antiretroviral Therapy on the Risk for Hodgkin Lymphoma among People with Human Immunodeficiency Virus Infection","volume":"24","author":"Goedert","year":"2012","journal-title":"Curr. Opin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2008.19.6626","article-title":"Highly Active Antiretroviral Therapy and the Incidence of Non\u2013AIDS-Defining Cancers in People with HIV Infection","volume":"27","author":"Powles","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood-2006-05-024109","article-title":"Hodgkin Lymphoma and Immunodeficiency in Persons with HIV\/AIDS","volume":"108","author":"Biggar","year":"2006","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e00813-18","DOI":"10.1128\/JVI.00813-18","article-title":"Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice","volume":"92","author":"Coleman","year":"2018","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"20160271","DOI":"10.1098\/rstb.2016.0271","article-title":"Epstein\u2013Barr Virus-Associated Lymphomas","volume":"372","author":"Rickinson","year":"2017","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.semdp.2017.04.003","article-title":"Human Immunodeficiency Virus (HIV) and Epstein-Barr Virus (EBV) Related Lymphomas, Pathology View Point","volume":"34","author":"Fend","year":"2017","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Verma, M. (2015). Epigenetic Regulation of HIV, AIDS, and AIDS-Related Malignancies. Cancer Epigenetics: Risk Assessment, Diagnosis, Treatment, and Prognosis, Springer. Methods in Molecular Biology.","DOI":"10.1007\/978-1-4939-1804-1_21"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.chom.2014.02.011","article-title":"Human Viral Oncogenesis: A Cancer Hallmarks Analysis","volume":"15","author":"Mesri","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.semcancer.2015.03.009","article-title":"Microenvironmental Abnormalities Induced by Viral Cooperation: Impact on Lymphomagenesis","volume":"34","author":"Carbone","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1182\/blood-2014-11-599951","article-title":"The Tumor Virus Landscape of AIDS-Related Lymphomas","volume":"125","author":"Arvey","year":"2015","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2015-11-681411","article-title":"A Lymphomagenic Role for HIV beyond Immune Suppression?","volume":"127","author":"Dolcetti","year":"2016","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fmicb.2015.00556","article-title":"The Presence of Epstein-Barr Virus Significantly Impacts the Transcriptional Profile in Immunodeficiency-Associated Burkitt Lymphoma","volume":"6","author":"Navari","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/imr.12067","article-title":"Insights into B Cells and HIV-Specific B-Cell Responses in HIV-Infected Individuals","volume":"254","author":"Moir","year":"2013","journal-title":"Immunol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-11-3169","article-title":"Epstein-Barr Virus Infection and Expression of B-Cell Oncogenic Markers in HIV-Related Diffuse Large B-Cell Lymphoma","volume":"18","author":"Chao","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Navari, M., Etebari, M., Ibrahimi, M., Leoncini, L., and Piccaluga, P.P. (2018). Pathobiologic Roles of Epstein\u2013Barr Virus-Encoded MicroRNAs in Human Lymphomas. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041168"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.micinf.2011.07.007","article-title":"The Role of MicroRNAs in Epstein-Barr Virus Latency and Lytic Reactivation","volume":"13","author":"Forte","year":"2011","journal-title":"Microbes Infect. Inst. Pasteur"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Rosemarie, Q., and Sugden, B. (2020). Epstein\u2013Barr Virus: How Its Lytic Phase Contributes to Oncogenesis. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111824"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1080\/10428190801911662","article-title":"van Immune Surveillance of EBV-Infected B Cells and the Development of Non-Hodgkin Lymphomas in Immunocompromised Patients","volume":"49","author":"Pietersma","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12102","DOI":"10.1128\/JVI.05607-11","article-title":"Antigen-Dependent and -Independent Mechanisms of T and B Cell Hyperactivation during Chronic HIV-1 Infection","volume":"85","author":"Haas","year":"2011","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/cid\/ciy542","article-title":"Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus\u2013Related Lymphomas","volume":"68","author":"Muncunill","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/QAD.0b013e32835e069d","article-title":"Poor Outcome of HIV-Infected Patients with Plasmablastic Lymphoma: Results from the German AIDS-Related Lymphoma Cohort Study","volume":"27","author":"Schommers","year":"2013","journal-title":"AIDS"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11060-019-03208-w","article-title":"Prognostic Markers for Immunodeficiency-Associated Primary Central Nervous System Lymphoma","volume":"144","author":"Kaulen","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Pei, Y., Wong, J.H.Y., and Robertson, E.S. (2020). Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas. Cancers, 12.","DOI":"10.3390\/cancers12092565"},{"key":"ref_29","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC). [4th ed.]."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/EDBK_242547","article-title":"Evolving Treatments for Primary Central Nervous System Lymphoma","volume":"39","author":"Ferreri","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"153192","DOI":"10.1016\/j.prp.2020.153192","article-title":"HIV Prevalence in Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis","volume":"216","author":"Franca","year":"2020","journal-title":"Pathol.-Res. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.23487","article-title":"Cancer Risk in People Infected with Human Immunodeficiency Virus in the United States","volume":"123","author":"Engels","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/QAD.0000000000000624","article-title":"HIV-Infection Impact on Clinical\u2013Biological Features and Outcome of Diffuse Large B-Cell Lymphoma Treated with R-CHOP in the Combination Antiretroviral Therapy Era","volume":"29","author":"Baptista","year":"2015","journal-title":"AIDS"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2011.03.003","article-title":"Gammaherpesvirus and Lymphoprolliferative Disorders in Immunocompromised Patients","volume":"305","author":"Cesarman","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3389\/fonc.2020.01723","article-title":"Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals","volume":"10","author":"Shindiapina","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/10428194.2013.813499","article-title":"Molecular Characteristics of Diffuse Large B-Cell Lymphoma in Human Immunodeficiency Virus-Infected and -Uninfected Patients in the Pre-Highly Active Antiretroviral Therapy and Pre-Rituximab Era","volume":"55","author":"Morton","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The Role of Tumor Histogenesis, FDG-PET, and Short-Course EPOCH with Dose-Dense Rituximab (SC-EPOCH-RR) in HIV-Associated Diffuse Large B-Cell Lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/10428194.2018.1512711","article-title":"Using the Lymph2Cx Assay for Assessing Cell-of-Origin Subtypes of HIV-Related Diffuse Large B-Cell Lymphoma","volume":"60","author":"Baptista","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/QAD.0000000000001652","article-title":"Outcomes for HIV-Associated Diffuse Large B-Cell Lymphoma in the Modern Combined Antiretroviral Therapy Era","volume":"31","author":"Besson","year":"2017","journal-title":"AIDS"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cncr.21562","article-title":"Changes in Acquired Immunodeficiency Syndrome-Related Non-Hodgkin Lymphoma in the Era of Highly Active Antiretroviral Therapy","volume":"106","author":"Diamond","year":"2006","journal-title":"Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00415-015-7713-8","article-title":"Neurological Complications of HIV Infection in Pre-HAART and HAART Era: A Retrospective Study","volume":"262","author":"Matinella","year":"2015","journal-title":"J. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/CCO.0b013e32834b6adc","article-title":"The Management of Primary Central Nervous System Lymphoma Related to AIDS in the HAART Era","volume":"23","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1086\/420934","article-title":"Predictive Value of Polymerase Chain Reaction of Cerebrospinal Fluid for Detection of Epstein-Barr Virus to Establish the Diagnosis of HIV-Related Primary Central Nervous System Lymphoma","volume":"38","author":"Ivers","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/jnci\/90.5.364","article-title":"Minimally Invasive Diagnosis of Acquired Immunodeficiency Syndrome-Related Primary Central Nervous System Lymphoma","volume":"90","author":"Cingolani","year":"1998","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/00002030-199610090-00004","article-title":"Polymerase Chain Reaction on Cerebrospinal Fluid for Diagnosis of Virus-Associated Opportunistic Diseases of the Central Nervous System in HIV-Infected Patients","volume":"10","author":"Cinque","year":"1996","journal-title":"AIDS"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fonc.2019.00109","article-title":"Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders","volume":"9","author":"Crombie","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1158\/0008-5472.CAN-07-5126","article-title":"EBV MicroRNAs in Primary Lymphomas and Targeting of CXCL-11 by Ebv-Mir-BHRF1-3","volume":"68","author":"Xia","year":"2008","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/cam4.1006","article-title":"Next\u2013generation Sequencing of MiRNAs in Clinical Samples of Epstein\u2013Barr Virus\u2013associated B\u2013cell Lymphomas","volume":"6","author":"Sakamoto","year":"2017","journal-title":"Cancer Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/leu.2015.285","article-title":"EBV-MiR-BHRF1-2 Targets PRDM1\/Blimp1: Potential Role in EBV Lymphomagenesis","volume":"30","author":"Ma","year":"2016","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/leu.2011.189","article-title":"Epstein-Barr Virus MicroRNAs Repress BCL6 Expression in Diffuse Large B-Cell Lymphoma","volume":"26","author":"Vargiu","year":"2012","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hon.2465","article-title":"Epstein-Barr Virus Lytic Cycle Involvement in Diffuse Large B Cell Lymphoma","volume":"36","author":"Cohen","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2013-03-488171","article-title":"The Microenvironment of AIDS-Related Diffuse Large B-Cell Lymphoma Provides Insight into the Pathophysiology and Indicates Possible Therapeutic Strategies","volume":"122","author":"Liapis","year":"2013","journal-title":"Blood"},{"key":"ref_54","first-page":"1","article-title":"Functions of the HIV-1 Matrix Protein P17","volume":"29","author":"Fiorentini","year":"2006","journal-title":"New Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"14331","DOI":"10.1073\/pnas.1514748112","article-title":"Role of HIV-1 Matrix Protein P17 Variants in Lymphoma Pathogenesis","volume":"112","author":"Dolcetti","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/ijc.29494","article-title":"A Natural HIV P17 Protein Variant Up-Regulates the LMP-1 EBV Oncoprotein and Promotes the Growth of EBV-Infected B-Lymphocytes: Implications for EBV-Driven Lymphomagenesis in the HIV Setting","volume":"137","author":"Martorelli","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.semcancer.2013.08.004","article-title":"Lymphomas Occurring Specifically in HIV-Infected Patients: From Pathogenesis to Pathology","volume":"23","author":"Gloghini","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/B978-0-444-63849-6.00014-1","article-title":"Chapter 14\u2014Primary CNS lymphoma in HIV infection","volume":"Volume 152","author":"Brew","year":"2018","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_59","first-page":"e2009032","article-title":"EBV and HIV-Related Lymphoma","volume":"1","author":"Bibas","year":"2009","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Gasser, O., Bihl, F.K., Wolbers, M., Loggi, E., Steffen, I., Hirsch, H.H., G\u00fcnthard, H.F., Walker, B.D., Brander, C., and Battegay, M. (2007). HIV Patients Developing Primary CNS Lymphoma Lack EBV-Specific CD4+ T Cell Function Irrespective of Absolute CD4+ T Cell Counts. PLOS Med., 4.","DOI":"10.1371\/journal.pmed.0040096"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.clml.2014.06.020","article-title":"HIV-Related Hematological Malignancies: A concise review","volume":"14","author":"Rios","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/ijc.32381","article-title":"Enhanced DNA Repair and Genomic Stability Identify a Novel HIV\u2013related Diffuse Large B\u2013cell Lymphoma Signature","volume":"145","author":"Maguire","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1200\/JCO.2008.20.5450","article-title":"Immunophenotypic Analysis of AIDS-Related Diffuse Large B-Cell Lymphoma and Clinical Implications in Patients from AIDS Malignancies Consortium Clinical Trials 010 and 034","volume":"27","author":"Chadburn","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-010-0252-3","article-title":"Primary CNS Lymphoma in HIV Positive and Negative Patients: Comparison of Clinical Characteristics, Outcome and Prognostic Factors","volume":"101","author":"Bayraktar","year":"2011","journal-title":"J. Neurooncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/neuonc\/now155","article-title":"Long-Term Survival in AIDS-Related Primary Central Nervous System Lymphoma","volume":"19","author":"Gupta","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1089\/aid.2011.0259","article-title":"Clinical Presentation, Treatment, and Outcomes among 65 Patients with HIV-Associated Lymphoma Treated at the University of North Carolina, 2000\u20132010","volume":"28","author":"Gopal","year":"2012","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1365-2141.1995.tb05205.x","article-title":"Evaluation of Cerebrospinal Fluid EBV\u2013DNA and IL\u201310 as Markers for in Vivo Diagnosis of AIDS\u2013related Primary Central Nervous System Lymphoma","volume":"90","author":"Antinori","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2007.06943.x","article-title":"Safety and Efficacy of Cyclophosphamide, Adriamycin, Vincristine, Prednisone and Rituximab in Patients with Human Immunodeficiency Virus-Associated Diffuse Large B-Cell Lymphoma: Results of a Phase II Trial","volume":"140","author":"Ribera","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse Large B-Cell Lymphoma: 2019 Update on Diagnosis, Risk Stratification, and Treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for Haematopoietic Stem Cell Transplantation for Haematological Diseases, Solid Tumours and Immune Disorders: Current Practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/neuonc\/noy192","article-title":"Comprehensive Approach to Diagnosis and Treatment of Newly Diagnosed Primary CNS Lymphoma","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro-Oncology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1002\/cncr.30965","article-title":"Diagnosis and Management of Primary Central Nervous System Lymphoma","volume":"123","author":"Han","year":"2017","journal-title":"Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"39.e1","DOI":"10.1016\/j.medcli.2017.11.037","article-title":"GESIDA\/PETHEMA Recommendations on the Diagnosis and Treatment of Lymphomas in Patients Infected by the Human Immunodeficiency Virus","volume":"151","author":"Miralles","year":"2018","journal-title":"Med. Clin."},{"key":"ref_74","unstructured":"Graham, B.S., and Lynch, D.T. (2021). Burkitt Lymphoma. StatPearls, StatPearls Publishing."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e516047","DOI":"10.1155\/2010\/516047","article-title":"Burkitt Lymphoma: Pathogenesis and Immune Evasion","volume":"2010","author":"God","year":"2010","journal-title":"J. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/1097-0142(196103\/04)14:2<258::AID-CNCR2820140206>3.0.CO;2-7","article-title":"Malignant Lymphoma in African Children. I. A Clinical Syndrome","volume":"14","author":"Burkitt","year":"1961","journal-title":"Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1200\/JCO.1998.16.12.3788","article-title":"Burkitt-like Lymphomas in AIDS Patients: Characterization within a Series of 103 Human Immunodeficiency Virus-Associated Non-Hodgkin\u2019s Lymphomas. Burkitt\u2019s Lymphoma Study Group","volume":"16","author":"Davi","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/leu.2011.156","article-title":"The Different Epidemiologic Subtypes of Burkitt Lymphoma Share a Homogenous Micro RNA Profile Distinct from Diffuse Large B-Cell Lymphoma","volume":"25","author":"Lenze","year":"2011","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apm.12078","article-title":"Epstein-Barr Virus Patterns in U.S. Burkitt Lymphoma Tumors from the SEER Residual Tissue Repository during 1979\u20132009","volume":"122","author":"Mbulaiteye","year":"2014","journal-title":"APMIS Acta Pathol. Microbiol. Immunol. Scand."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2141.2005.05613.x","article-title":"AIDS-Related Lymphomas: From Pathogenesis to Pathology","volume":"130","author":"Carbone","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-03-275917","article-title":"AIDS-Related Burkitt Lymphoma in the United States: What Do Age and CD4 Lymphocyte Patterns Tell Us about Etiology and\/or Biology?","volume":"116","author":"Simard","year":"2010","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1200\/JCO.2005.11.973","article-title":"AIDS-Related Burkitt\u2019s Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre\u2013Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival with Standard Chemotherapy","volume":"23","author":"Lim","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/djt158","article-title":"Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era","volume":"105","author":"Gopal","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","article-title":"How I Treat HIV-Associated Lymphoma","volume":"119","author":"Dunleavy","year":"2012","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1470-2045(03)00957-4","article-title":"Emerging Pathways in the Development of AIDS-Related Lymphomas","volume":"4","author":"Carbone","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ijc.1404","article-title":"Antagonistic Effects of C-Myc and Epstein-Barr Virus Latent Genes on the Phenotype of Human B Cells","volume":"93","author":"Pajic","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10989","DOI":"10.1073\/pnas.1832776100","article-title":"The EBV Nuclear Antigen 1 (EBNA1) Enhances B Cell Immortalization Several Thousandfold","volume":"100","author":"Humme","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.semcancer.2009.07.007","article-title":"How Does Epstein\u2013Barr Virus (EBV) Complement the Activation of Myc in the Pathogenesis of Burkitt\u2019s Lymphoma?","volume":"19","author":"Allday","year":"2009","journal-title":"Semin. Cancer Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ijc.11224","article-title":"Epstein-Barr Virus Nuclear Antigen-1 and Myc Cooperate in Lymphomagenesis","volume":"106","author":"Drotar","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1038\/bcj.2014.75","article-title":"Hypermethylation of the Tumor Suppressor Gene PRDM1\/Blimp-1 Supports a Pathogenetic Role in EBV-Positive Burkitt Lymphoma","volume":"4","author":"Zhang","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1073\/pnas.0901036106","article-title":"The Epstein\u2013Barr Virus Bcl-2 Homolog, BHRF1, Blocks Apoptosis by Binding to a Limited Amount of Bim","volume":"106","author":"Desbien","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/s41418-019-0435-1","article-title":"EBV BCL-2 Homologue BHRF1 Drives Chemoresistance and Lymphomagenesis by Inhibiting Multiple Cellular pro-Apoptotic Proteins","volume":"27","author":"Fitzsimmons","year":"2020","journal-title":"Cell Death Differ."},{"key":"ref_93","first-page":"1929","article-title":"Functional and Physical Interaction between P53 and BZLF1: Implications for Epstein-Barr Virus Latency","volume":"14","author":"Zhang","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-9378-9-12","article-title":"The Epstein Barr-Encoded BART-6-3p MicroRNA Affects Regulation of Cell Growth and Immuno Response in Burkitt Lymphoma","volume":"9","author":"Ambrosio","year":"2014","journal-title":"Infect. Agents Cancer"},{"key":"ref_95","first-page":"4114","article-title":"Epstein-Barr Virus (EBV)-BamHI-A Rightward Transcript (BART)-6 and Cellular MicroRNA-142 Synergistically Compromise Immune Defense of Host Cells in EBV-Positive Burkitt Lymphoma","volume":"22","author":"Zhou","year":"2016","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Ungerleider, N., Bullard, W., Kara, M., Wang, X., Roberts, C., Renne, R., Tibbetts, S., and Flemington, E.K. (2021). EBV MiRNAs Are Potent Effectors of Tumor Cell Transcriptome Remodeling in Promoting Immune Escape. PLOS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009217"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1093\/emboj\/19.24.6742","article-title":"Epstein\u2013Barr Virus-Encoded Poly(A)\u2212 RNA Supports Burkitt\u2019s Lymphoma Growth through Interleukin-10 Induction","volume":"19","author":"Kitagawa","year":"2000","journal-title":"EMBO J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/emboj\/21.5.954","article-title":"Epstein\u2013Barr Virus RNA Confers Resistance to Interferon-\u03b1-Induced Apoptosis in Burkitt\u2019s Lymphoma","volume":"21","author":"Nanbo","year":"2002","journal-title":"EMBO J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-9378-9-34","article-title":"The Role of EBV in the Pathogenesis of Burkitt\u2019s Lymphoma: An Italian Hospital Based Survey","volume":"9","author":"Pannone","year":"2014","journal-title":"Infect. Agents Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beha.2018.07.013","article-title":"Burkitt Lymphoma- a Rare but Challenging Lymphoma","volume":"31","author":"Casulo","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","article-title":"Adult Burkitt Leukemia and Lymphoma","volume":"104","author":"Blum","year":"2004","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/apc.2007.0124","article-title":"Review: Improving Outcomes for Patients with Burkitt Lymphoma and HIV","volume":"22","author":"Blinder","year":"2008","journal-title":"AIDS Patient Care STDs"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.27918","article-title":"Dose-Intensive Chemotherapy Including Rituximab in Burkitt\u2019s Leukemia or Lymphoma Regardless of Human Immunodeficiency Virus Infection Status","volume":"119","author":"Ribera","year":"2013","journal-title":"Cancer"},{"key":"ref_104","first-page":"445","article-title":"Lack of Influence of Human Immunodeficiency Virus Infection Status in the Response to Therapy and Survival of Adult Patients with Mature B-Cell Lymphoma or Leukemia. Results of the PETHEMA-LAL3\/97 Study","volume":"88","author":"Oriol","year":"2003","journal-title":"Haematologica"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the Addition of Rituximab to CODOX-M\/IVAC for Burkitt\u2019s Lymphoma: A Retrospective Analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-Intensity Therapy in Adults with Burkitt\u2019s Lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/ajh.25955","article-title":"Survival Analysis in Treated Plasmablastic Lymphoma Patients: A Population-Based Study","volume":"95","author":"Florindez","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3109\/10428194.2010.516040","article-title":"Clinical and Pathological Differences between Human Immunodeficiency Virus-Positive and Human Immunodeficiency Virus-Negative Patients with Plasmablastic Lymphoma","volume":"51","author":"Castillo","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdw684","article-title":"Clinical Characteristics and Prognostic Factors of Plasmablastic Lymphoma Patients: Analysis of 135 Patients from the LYSA Group","volume":"28","author":"Tchernonog","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic Lymphomas of the Oral Cavity: A New Entity Associated with the Human Immunodeficiency Virus Infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/hupa.2002.124723","article-title":"AIDS-Related Non-Hodgkin\u2019s Lymphomas: From Pathology and Molecular Pathogenesis to Treatment","volume":"33","author":"Carbone","year":"2002","journal-title":"Hum. Pathol."},{"key":"ref_112","first-page":"399","article-title":"Plasmablastic Lymphoma","volume":"147","author":"Sancho","year":"2016","journal-title":"Med. Cl\u00edn. Engl. Ed."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The Biology and Treatment of Plasmablastic Lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/PAS.0000000000000234","article-title":"Clinicopathologic Comparison of Plasmablastic Lymphoma in HIV-Positive, Immunocompetent, and Posttransplant Patients: Single-Center Series of 25 Cases and Meta-Analysis of 277 Reported Cases","volume":"38","author":"Morscio","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/annonc\/mdh399","article-title":"CD20-Negative Large-Cell Lymphoma with Plasmablastic Features: A Clinically Heterogenous Spectrum in Both HIV-Positive and -Negative Patients","volume":"15","author":"Chiao","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_116","first-page":"2682","article-title":"MAP-Kinase and JAK-STAT Pathways Dysregulation in Plasmablastic Lymphoma","volume":"106","author":"Nicolae","year":"2020","journal-title":"Haematologica"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1038\/s41467-021-25405-w","article-title":"Molecular and Functional Profiling Identifies Therapeutically Targetable Vulnerabilities in Plasmablastic Lymphoma","volume":"12","author":"Frontzek","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3324\/haematol.2020.251579","article-title":"Genetic Lesions in MYC and STAT3 Drive Oncogenic Transcription Factor Overexpression in Plasmablastic Lymphoma","volume":"106","author":"Magunacelaya","year":"2020","journal-title":"Haematologica"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2643-3230.BCD-20-0051","article-title":"Genomic Characterization of HIV-Associated Plasmablastic Lymphoma Identifies Pervasive Mutations in the JAK\u2013STAT Pathway","volume":"1","author":"Liu","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/BLCTT.S142814","article-title":"Plasmablastic Lymphoma: Current Perspectives","volume":"8","author":"Lopez","year":"2018","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","article-title":"IG\/MYC Rearrangements Are the Main Cytogenetic Alteration in Plasmablastic Lymphomas","volume":"34","author":"Valera","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/modpathol.2016.162","article-title":"Plasmablastic Lymphoma Phenotype Is Determined by Genetic Alterations in MYC and PRDM1","volume":"30","author":"Ranchal","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2017.180893","article-title":"Incidence and Risk Factors for Relapses in HIV-Associated Non-Hodgkin Lymphoma as Observed in the German HIV-Related Lymphoma Cohort Study","volume":"103","author":"Schommers","year":"2018","journal-title":"Haematologica"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-015-0163-z","article-title":"Stage, Age, and EBV Status Impact Outcomes of Plasmablastic Lymphoma Patients: A Clinicopathologic Analysis of 61 Patients","volume":"8","author":"Loghavi","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1126\/science.276.5312.596","article-title":"Repression of C-Myc Transcription by Blimp-1, an Inducer of Terminal B Cell Differentiation","volume":"276","author":"Lin","year":"1997","journal-title":"Science"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1074-7613(02)00335-7","article-title":"Blimp-1 Orchestrates Plasma Cell Differentiation by Extinguishing the Mature B Cell Gene Expression Program","volume":"17","author":"Shaffer","year":"2002","journal-title":"Immunity"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"107356","DOI":"10.18632\/oncotarget.22219","article-title":"MicroRNAs Sequencing Unveils Distinct Molecular Subgroups of Plasmablastic Lymphoma","volume":"8","author":"Ambrosio","year":"2017","journal-title":"Oncotarget"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e1486950","DOI":"10.1080\/2162402X.2018.1486950","article-title":"EBV Infection Determines the Immune Hallmarks of Plasmablastic Lymphoma","volume":"7","author":"Gravelle","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.21250","article-title":"HIV-Associated Plasmablastic Lymphoma: Lessons Learned from 112 Published Cases","volume":"83","author":"Castillo","year":"2008","journal-title":"Am. J. Hematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human Immunodeficiency Virus-Associated Plasmablastic Lymphoma","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","article-title":"Prognostic Factors in Chemotherapy-Treated Patients with HIV-Associated Plasmablastic Lymphoma","volume":"15","author":"Castillo","year":"2010","journal-title":"Oncologist"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s12185-016-2082-3","article-title":"Clinical and Pathological Aspects of Human Immunodeficiency Virus-Associated Plasmablastic Lymphoma: Analysis of 24 Cases","volume":"104","author":"Koizumi","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3324\/haematol.2016.141978","article-title":"Immune-Checkpoint Expression in Epstein-Barr Virus Positive and Negative Plasmablastic Lymphoma: A Clinical and Pathological Study in 82 Patients","volume":"101","author":"Laurent","year":"2016","journal-title":"Haematologica"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus EPOCH Is Effective as Frontline Treatment in Patients with Plasmablastic Lymphoma","volume":"184","author":"Castillo","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.bbmt.2014.06.009","article-title":"Hematopoietic Cell Transplantation for Plasmablastic Lymphoma: A Review","volume":"20","author":"Castillo","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10428194.2014.911867","article-title":"Plasmablastic Lymphoma among Human Immunodeficiency Virus-Positive Patients: Results of a Single Center\u2019s Experience","volume":"56","author":"Cattaneo","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1200\/JCO.2005.07.084","article-title":"Prognostic Factors and Outcome of Human Herpesvirus 8\u2013Associated Primary Effusion Lymphoma in Patients with AIDS","volume":"23","author":"Boulanger","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Hu, Z., Pan, Z., Chen, W., Shi, Y., Wang, W., Yuan, J., Wang, E., Zhang, S., Kurt, H., and Mai, B. (2021). Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases. Cancers, 13.","DOI":"10.3390\/cancers13040878"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/01.pas.0000138177.10829.5c","article-title":"KSHV-Positive Solid Lymphomas Represent an Extra-Cavitary Variant of Primary Effusion Lymphoma","volume":"28","author":"Chadburn","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.2147\/OTT.S167392","article-title":"Primary Effusion Lymphoma: Current Perspectives","volume":"11","author":"Narkhede","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1038\/bcj.2014.6","article-title":"Primary Effusion Lymphoma in an Elderly Patient Effectively Treated by Lenalidomide: Case Report and Review of Literature","volume":"4","author":"Antar","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood-2018-03-791426","article-title":"Biology and Management of Primary Effusion Lymphoma","volume":"132","author":"Shimada","year":"2018","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"10399","DOI":"10.1073\/pnas.1630810100","article-title":"Kaposi\u2019s Sarcoma-Associated Herpesvirus-Infected Primary Effusion Lymphoma Has a Plasma Cell Gene Expression Profile","volume":"100","author":"Jenner","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood.V91.7.2475","article-title":"Mechanisms of Growth Control of Kaposi\u2019s Sarcoma\u2013Associated Herpes Virus\u2013Associated Primary Effusion Lymphoma Cells","volume":"91","author":"Asou","year":"1998","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"13745","DOI":"10.1074\/jbc.M110480200","article-title":"The Human Herpes Virus 8-Encoded Viral FLICE Inhibitory Protein Physically Associates with and Persistently Activates the I\u03baB Kinase Complex","volume":"277","author":"Liu","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1182\/blood-2010-12-323659","article-title":"Tumor Suppressor Genes FHIT and WWOX Are Deleted in Primary Effusion Lymphoma (PEL) Cell Lines","volume":"118","author":"Roy","year":"2011","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1182\/blood.V90.3.1186.1186_1186_1191","article-title":"Epstein-Barr Virus Latent Gene Expression in Primary Effusion Lymphomas Containing Kaposi\u2019s Sarcoma\u2013Associated Herpesvirus\/Human Herpesvirus-8","volume":"90","author":"Horenstein","year":"1997","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi\u2019s Sarcoma-Associated Herpesvirus-like DNA Sequences in AIDS-Related Body-Cavity-Based Lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Cai, X., Sch\u00e4fer, A., Lu, S., Bilello, J.P., Desrosiers, R.C., Edwards, R., Raab-Traub, N., and Cullen, B.R. (2006). Epstein\u2013Barr Virus MicroRNAs Are Evolutionarily Conserved and Differentially Expressed. PLoS Pathog., 2.","DOI":"10.1371\/journal.ppat.0020023"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/17474086.2017.1326815","article-title":"Multiple Viral Infections in Primary Effusion Lymphoma: A Model of Viral Cooperation in Lymphomagenesis","volume":"10","author":"Gloghini","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chom.2017.06.009","article-title":"Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression","volume":"22","author":"McHugh","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"E11379","DOI":"10.1073\/pnas.1810128115","article-title":"Epstein-Barr Virus Enhances Genome Maintenance of Kaposi Sarcoma-Associated Herpesvirus","volume":"115","author":"Bigi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1002\/cncr.30112","article-title":"Human Immunodeficiency Virus-Associated Lymphomas in the Antiretroviral Therapy Era: Analysis of the National Cancer Data Base","volume":"122","author":"Olszewski","year":"2016","journal-title":"Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/hon.2372","article-title":"Clinical Characteristics and Survival Outcome of Primary Effusion Lymphoma: A Review of 105 Patients","volume":"35","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","article-title":"Clinical Features and Outcome of Primary Effusion Lymphoma in HIV-Infected Patients: A Single-Institution Study","volume":"21","author":"Simonelli","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.3109\/10428194.2012.694075","article-title":"Prognosis in Primary Effusion Lymphoma Is Associated with the Number of Body Cavities Involved","volume":"53","author":"Castillo","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ajh.24251","article-title":"Classic and Extracavitary Primary Effusion Lymphoma in 51 HIV-Infected Patients from a Single Institution","volume":"91","author":"Guillet","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00002030-200101260-00023","article-title":"Long-Term Remission of an AIDS-Related Primary Effusion Lymphoma with Antiviral Therapy","volume":"15","author":"Hocqueloux","year":"2001","journal-title":"AIDS"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2019-01-893339","article-title":"Viral, Immunologic, and Clinical Features of Primary Effusion Lymphoma","volume":"133","author":"Lurain","year":"2019","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000446315","article-title":"Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?","volume":"9","author":"Jessamy","year":"2016","journal-title":"Case Rep. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1532\/IJH97.A30510","article-title":"Successful Eradication of Relapsed Primary Effusion Lymphoma with High-Dose Chemotherapy and Autologous Stem Cell Transplantation in a Patient Seronegative for Human Immunodeficiency Virus","volume":"83","author":"Won","year":"2006","journal-title":"Int. J. Hematol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bbmt.2008.01.010","article-title":"Successful Reduced-Intensity Conditioning Allogeneic HSCT for HIV-Related Primary Effusion Lymphoma","volume":"14","author":"Bryant","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3324\/haematol.10479","article-title":"Results of Treatment with Doxorubicin, Bleomycin, Vinblastine and Dacarbazine and Highly Active Antiretroviral Therapy in Advanced Stage, Human Immunodeficiency Virus-Related Hodgkin\u2019s Lymphoma","volume":"92","author":"Xicoy","year":"2007","journal-title":"Haematologica"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1182\/blood-2008-12-195388","article-title":"Comparable Survival between HIV+ and HIV- Non-Hodgkin and Hodgkin Lymphoma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation","volume":"113","author":"Balsalobre","year":"2009","journal-title":"Blood"},{"key":"ref_165","first-page":"234","article-title":"Characterization of HIV-Associated Hodgkin\u2019s Lymphoma in HIV-Infected Patients: A Single-Center Experience","volume":"11","author":"Ruiz","year":"2012","journal-title":"J. Int. Assoc. Physicians AIDS Care Chic. Ill 2002"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1055-9965.EPI-13-0865","article-title":"Prevalence of HIV Infection among U.S. Hodgkin Lymphoma Cases","volume":"23","author":"Shiels","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jnci\/dji072","article-title":"Cancer Risk in the Swiss HIV Cohort Study: Associations with Immunodeficiency, Smoking, and Highly Active Antiretroviral Therapy","volume":"97","author":"Clifford","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e2019004","DOI":"10.4084\/mjhid.2019.004","article-title":"Hiv and Lymphoma: From Epidemiology to Clinical Management","volume":"11","author":"Re","year":"2019","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/hiv.12200","article-title":"van Krznaric, I.; M\u00fcller, M.; et al. Hodgkin Lymphoma Is as Common as Non-Hodgkin Lymphoma in HIV-Positive Patients with Sustained Viral Suppression and Limited Immune Deficiency: A Prospective Cohort Study","volume":"16","author":"Hoffmann","year":"2015","journal-title":"HIV Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2011-02-339275","article-title":"HIV-Associated Hodgkin Lymphoma during the First Months on Combination Antiretroviral Therapy","volume":"118","author":"Lanoy","year":"2011","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1182\/blood-2010-08-301531","article-title":"HIV-1\u2013Related Hodgkin Lymphoma in the Era of Combination Antiretroviral Therapy: Incidence and Evolution of CD4+ T-Cell Lymphocytes","volume":"117","author":"Bohlius","year":"2011","journal-title":"Blood"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0959-8049(01)00105-8","article-title":"Pathogenetic and Histogenetic Features of HIV-Associated Hodgkin\u2019s Disease","volume":"37","author":"Dolcetti","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s002770100294","article-title":"Histological Subtypes of Hodgkin\u2019s Disease in the Setting of HIV Infection","volume":"80","author":"Rapezzi","year":"2001","journal-title":"Ann. Hematol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin Disease: Hodgkin and Reed-Sternberg Cells Picked from Histological Sections Show Clonal Immunoglobulin Gene Rearrangements and Appear to Be Derived from B Cells at Various Stages of Development","volume":"91","author":"Rajewsky","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular Biology of Hodgkin Lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.V81.2.496.496","article-title":"High Prevalence of Epstein-Barr Virus in the Reed-Sternberg Cells of Hodgkin\u2019s Disease Occurring in Peru","volume":"81","author":"Chang","year":"1993","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/path.1711670406","article-title":"Frequent Expression of Epstein-Barr Virus Latent Membrane Protein-1 in Tumour Cells of Hodgkin\u2019s Disease in HIV-Positive Patients","volume":"167","author":"Audouin","year":"1992","journal-title":"J. Pathol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1008337100424","article-title":"Epstein-Barr Virus Association in Classical Hodgkin\u2019s Disease Provides Survival Advantage to Patients and Correlates with Higher Expression of Proliferation Markers in Reed-Sternberg Cells","volume":"11","author":"Naresh","year":"2000","journal-title":"Ann. Oncol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1038\/sj.onc.1206556","article-title":"Epstein\u2013Barr Virus and Oncogenesis: From Latent Genes to Tumours","volume":"22","author":"Young","year":"2003","journal-title":"Oncogene"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","article-title":"Epstein-Barr Virus LMP2A Drives B Cell Development and Survival in the Absence of Normal B Cell Receptor Signals","volume":"9","author":"Caldwell","year":"1998","journal-title":"Immunity"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2003-04-1018","article-title":"Epstein-Barr Virus (EBV) LMP2A Induces Alterations in Gene Transcription Similar to Those Observed in Reed-Sternberg Cells of Hodgkin Lymphoma","volume":"102","author":"Portis","year":"2003","journal-title":"Blood"},{"key":"ref_182","first-page":"151","article-title":"Latent Membrane Protein 2 (LMP2)","volume":"391","author":"Cen","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_183","first-page":"119","article-title":"The Latent Membrane Protein 1 (LMP1)","volume":"391","author":"Kieser","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/emboj\/17.6.1700","article-title":"Epstein-Barr Virus-Mediated B-Cell Proliferation Is Dependent upon Latent Membrane Protein 1, Which Simulates an Activated CD40 Receptor","volume":"17","author":"Kilger","year":"1998","journal-title":"EMBO J."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Post-Transplant Lymphoproliferative Disorders: Implications for Targeted Therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune Checkpoint Blockade in Hematologic Malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/ijc.30473","article-title":"The Impact of EBV and HIV Infection on the Microenvironmental Niche Underlying Hodgkin Lymphoma Pathogenesis","volume":"140","author":"Carbone","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1038\/bcj.2016.26","article-title":"The Microenvironment of Classical Hodgkin Lymphoma: Heterogeneity by Epstein\u2013Barr Virus Presence and Location within the Tumor","volume":"6","author":"Wu","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4049\/jimmunol.165.2.663","article-title":"Direct Immunosuppressive Effects of EBV-Encoded Latent Membrane Protein 1","volume":"165","author":"Dukers","year":"2000","journal-title":"J. Immunol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/modpathol.2012.217","article-title":"Spindle-Shaped CD163+ Rosetting Macrophages Replace CD4+ T-Cells in HIV-Related Classical Hodgkin Lymphoma","volume":"26","author":"Hartmann","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1182\/blood-2017-07-794529","article-title":"Role of Exosomes as a Proinflammatory Mediator in the Development of EBV-Associated Lymphoma","volume":"131","author":"Higuchi","year":"2018","journal-title":"Blood"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1309\/PNVQ0PQGXHVY6L7G","article-title":"HIV-Associated Hodgkin Lymphoma: A Clinicopathologic and Immunophenotypic Study of 45 Cases","volume":"121","author":"Thompson","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/QAD.0000000000000986","article-title":"Outcomes of HIV-Associated Hodgkin Lymphoma in the Era of Antiretroviral Therapy","volume":"30","author":"Olszewski","year":"2016","journal-title":"AIDS"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e26302","DOI":"10.1002\/pbc.26302","article-title":"Hodgkin Lymphoma, HIV, and Epstein\u2013Barr Virus in Malawi: Longitudinal Results from the Kamuzu Central Hospital Lymphoma Study","volume":"64","author":"Westmoreland","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2012.41.8137","article-title":"Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study","volume":"30","author":"Hentrich","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdg408","article-title":"BEACOPP Therapeutic Regimen for Patients with Hodgkin\u2019s Disease and HIV Infection","volume":"14","author":"Hartmann","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2004-04-1532","article-title":"Durable Remissions with Autologous Stem Cell Transplantation for High-Risk HIV-Associated Lymphomas","volume":"105","author":"Krishnan","year":"2005","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bbmt.2007.03.014","article-title":"Dose-Reduced Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation for Human Immunodeficiency Virus\u2013Associated Lymphoma: AIDS Malignancy Consortium Study 020","volume":"14","author":"Spitzer","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3109\/10428194.2015.1072766","article-title":"Whole Blood EBV-DNA Predicts Outcome in Diffuse Large B-Cell Lymphoma","volume":"57","author":"Tisi","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/cas.12812","article-title":"Prognostic Significance of Epstein\u2013Barr Virus DNA Detection in Pretreatment Serum in Diffuse Large B\u2013cell Lymphoma","volume":"106","author":"Okamoto","year":"2015","journal-title":"Cancer Sci."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood-2012-09-454694","article-title":"Plasma Epstein-Barr Virus DNA Predicts Outcome in Advanced Hodgkin Lymphoma: Correlative Analysis from a Large North American Cooperative Group Trial","volume":"121","author":"Kanakry","year":"2013","journal-title":"Blood"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2015-09-672030","article-title":"The Clinical Significance of EBV DNA in the Plasma and Peripheral Blood Mononuclear Cells of Patients with or without EBV Diseases","volume":"127","author":"Kanakry","year":"2016","journal-title":"Blood"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"M\u00fcnz, C. (2015). The Biology and Clinical Utility of EBV Monitoring in Blood. Epstein Barr Virus Volume 2: One Herpes Virus: Many Diseases, Springer International Publishing. Current Topics in Microbiology and Immunology.","DOI":"10.1007\/978-3-319-22834-1"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"12168","DOI":"10.1038\/srep12168","article-title":"Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma Predict Poor Outcome, Regardless of the Age","volume":"5","author":"Lu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1078-0432.CCR-05-2008","article-title":"Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin\u2019s Lymphoma","volume":"12","author":"Gandhi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/(SICI)1097-0215(19990820)84:4<442::AID-IJC20>3.0.CO;2-J","article-title":"Detection of Epstein-Barr Virus (EBV) Genomes in the Serum of Patients with EBV-Associated Hodgkin\u2019s Disease","volume":"84","author":"Gallagher","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1158\/1078-0432.CCR-10-3327","article-title":"The Viral Load of Epstein\u2013Barr Virus (EBV) DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma","volume":"17","author":"Hohaus","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1469-0691.2009.02922.x","article-title":"Clinical Characteristics, Outcome and the Role of Viral Load in Nontransplant Patients with Epstein--Barr Viraemia","volume":"16","author":"Martelius","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/cam4.2710","article-title":"High Pretreatment Plasma Epstein\u2013Barr Virus (EBV) DNA Level Is a Poor Prognostic Marker in HIV\u2013associated, EBV\u2013negative Diffuse Large B\u2013cell Lymphoma in Malawi","volume":"9","author":"Montgomery","year":"2019","journal-title":"Cancer Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.medcli.2010.02.041","article-title":"Plasma Epstein-Barr viral load measurement as a diagnostic marker of lymphoma in HIV-infected patients","volume":"135","author":"Navarro","year":"2010","journal-title":"Med. Cl\u00ednica"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10428194.2016.1179299","article-title":"Epstein-Barr Viral Loads and Serum Free Light Chains Levels Are Potential Follow-up Markers of HIV-Related Lymphomas","volume":"58","author":"Baptista","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_212","first-page":"191","article-title":"Epstein\u2013Barr Viral Load Is Associated to Response in AIDS-Related Lymphomas","volume":"30","author":"Tanaka","year":"2014","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/jmv.20238","article-title":"Epstein\u2013Barr Viral Load as a Marker of Lymphoma in AIDS Patients","volume":"75","author":"Fan","year":"2005","journal-title":"J. Med. Virol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/QAI.0b013e31819a22ec","article-title":"Epstein-Barr Virus Load in Whole Blood Correlates with HIV Surrogate Markers and Lymphoma: A French National Cross-Sectional Study","volume":"50","author":"Amiel","year":"2009","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1468-1293.2012.00998.x","article-title":"Blood Epstein\u2013Barr Virus DNA Load and Risk of Progression to AIDS-Related Systemic B Lymphoma","volume":"13","author":"Seng","year":"2012","journal-title":"HIV Med."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1086\/341460","article-title":"Absolute Level of Epstein-Barr Virus DNA in Human Immunodeficiency Virus Type 1 Infection Is Not Predictive of AIDS-Related Non-Hodgkin Lymphoma","volume":"186","author":"Wolthers","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/QAD.0000000000002839","article-title":"Prospective Evaluation of Blood Epstein\u2013Barr Virus DNA Load and Antibody Profile in HIV-Related Non-Hodgkin Lymphomas","volume":"35","author":"Lupo","year":"2021","journal-title":"AIDS"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12032-018-1099-2","article-title":"Blood Epstein\u2013Barr Virus DNA Does Not Predict Outcome in Advanced HIV-Associated Hodgkin Lymphoma","volume":"35","author":"Suardi","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/QAD.0000000000002129","article-title":"Epstein\u2013Barr Virus Biomarkers Have No Prognostic Value in HIV-Related Hodgkin Lymphoma in the Modern Combined Antiretroviral Therapy Era","volume":"33","author":"Lupo","year":"2019","journal-title":"AIDS"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment Factors Affecting Outcomes in HIV-Associated Non-Hodgkin Lymphomas: A Pooled Analysis of 1546 Patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/asheducation-2013.1.382","article-title":"Update on the Treatment of HIV-Associated Hematologic Malignancies","volume":"2013","author":"Little","year":"2013","journal-title":"Hematology"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/cid\/ciu174","article-title":"Management of HIV Infection in Patients with Cancer Receiving Chemotherapy","volume":"59","author":"Mayer","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","article-title":"Optimizing Treatment of HIV-Associated Lymphoma","volume":"134","author":"Noy","year":"2019","journal-title":"Blood"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.blre.2006.02.001","article-title":"CNS Prophylaxis in Lymphoma: Who to Target and What Therapy to Use","volume":"20","author":"Hill","year":"2006","journal-title":"Blood Rev."},{"key":"ref_225","first-page":"74","article-title":"Reca\u00edda en el sistema nervioso central en el linfoma B difuso de c\u00e9lula grande: Factores de riesgo","volume":"146","author":"Sancho","year":"2016","journal-title":"Med. Cl\u00edn."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3109\/10428194.2013.869326","article-title":"Central Nervous System Involvement in Diffuse Large B-Cell Lymphoma: An Analysis of Risks and Prevention Strategies in the Post-Rituximab Era","volume":"55","author":"Fletcher","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/14737140.6.3.335","article-title":"Non-Hodgkin\u2019s Lymphoma and the CNS: Prophylaxis and Therapy in Immunocompetent and HIV-Positive Individuals","volume":"6","author":"Mazhar","year":"2006","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3026(20)30115-0","article-title":"Treatment Management of Haematological Malignancies in People Living with HIV","volume":"7","author":"Re","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hiv.12136","article-title":"British HIV Association Guidelines for HIV-Associated Malignancies 2014","volume":"15","author":"Bower","year":"2014","journal-title":"HIV Med."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"986","DOI":"10.6004\/jnccn.2018.0066","article-title":"Cancer in People Living with HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Reid","year":"2018","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Navarro, J.-T., Molt\u00f3, J., Tapia, G., and Ribera, J.-M. (2021). Hodgkin Lymphoma in People Living with HIV. Cancers, 13.","DOI":"10.20944\/preprints202108.0420.v1"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1087057110379154","article-title":"Development of a High-Throughput Screen for Inhibitors of Epstein-Barr Virus EBNA1","volume":"15","author":"Thompson","year":"2010","journal-title":"J. Biomol. Screen."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"eaau5612","DOI":"10.1126\/scitranslmed.aau5612","article-title":"Structure-Based Design of Small-Molecule Inhibitors of EBNA1 DNA Binding Blocks Epstein-Barr Virus Latent Infection and Tumor Growth","volume":"11","author":"Messick","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1158\/1535-7163.MCT-05-0253","article-title":"Anti-CD70 Antibodies: A Potential Treatment for EBV CD70-Expressing Lymphomas","volume":"4","author":"Israel","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/intimm\/dxh401","article-title":"T Cell Re-Targeting to EBV Antigens Following TCR Gene Transfer: CD28-Containing Receptors Mediate Enhanced Antigen-Specific IFNgamma Production","volume":"18","author":"Schaft","year":"2006","journal-title":"Int. Immunol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.jcyt.2019.03.569","article-title":"CD19 Chimeric Antigen Receptor (CAR) Engineered Epstein-Barr Virus (EBV) Specific T Cells\u2014An off-the-Shelf, Allogeneic CAR T-Cell Immunotherapy Platform","volume":"21","author":"Shen","year":"2019","journal-title":"Cytotherapy"},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Quan, L., Chen, X., Liu, A., Zhang, Y., Guo, X., Yan, S., and Liu, Y. (2015). PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136476"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4143\/crt.2018.191","article-title":"Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus\u2012Positive and \u2012Negative Relapsed or Refractory Non-Hodgkin Lymphomas","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/bjc.2017.475","article-title":"A Novel Epstein-Barr Virus-Latent Membrane Protein-1-Specific T-Cell Receptor for TCR Gene Therapy","volume":"118","author":"Cho","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fonc.2019.00104","article-title":"Progress in EBV Vaccines","volume":"9","author":"Mautner","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3816\/CLM.2006.n.017","article-title":"AIDS Associated Malignancies Clinical Trials Consortium Antiviral and Immunomodulatory Treatment for AIDS-Related Primary Central Nervous System Lymphoma: AIDS Malignancies Consortium Pilot Study 019","volume":"6","author":"Aboulafia","year":"2006","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/088922299310809","article-title":"Treatment of AIDS-Related Primary Central Nervous System Lymphoma with Zidovudine, Ganciclovir, and Interleukin 2","volume":"15","author":"Raez","year":"1999","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1086\/499956","article-title":"Ganciclovir Is Associated with Low or Undetectable Epstein-Barr Virus DNA Load in Cerebrospinal Fluid of Patients with HIV-Related Primary Central Nervous System Lymphoma","volume":"42","author":"Bossolasco","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00001622-200109000-00008","article-title":"Induction of the Epstein\u2013Barr Virus Thymidine Kinase Gene with Concomitant Nucleoside Antivirals as a Therapeutic Strategy for Epstein\u2013Barr Virus\u2013Associated Malignancies","volume":"13","author":"Faller","year":"2001","journal-title":"Curr. Opin. Oncol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A Phase 1\/2 Trial of Arginine Butyrate and Ganciclovir in Patients with Epstein-Barr Virus\u2013Associated Lymphoid Malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1182\/blood.V114.22.4754.4754","article-title":"Short-Term Exposure to Arginine Butyrate, in Combination with Ganciclovir, Is as Effective as Continuous Exposure for Virus-Targeted Therapy of EBV-Positive Lymphomas","volume":"114","author":"Faller","year":"2009","journal-title":"Blood"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical Experience with Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients with Advanced Hematologic Malignancies","volume":"24","author":"Heaney","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"18511","DOI":"10.1200\/jco.2007.25.18_suppl.18511","article-title":"Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): Final Results of a Phase II Trial","volume":"25","author":"Crump","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed Death-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure","volume":"34","author":"Armand","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained Complete Responses in Patients with Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins","volume":"392","author":"Bollard","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1\u2013Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5534\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:25:48Z","timestamp":1760167548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":252,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cancers13215534"],"URL":"https:\/\/doi.org\/10.3390\/cancers13215534","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]}}}